Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 15/20 | 1.00 |
| ▸ | BCR | P11274 | 13/20 | 1.00 |
| ▸ | PDGFRA | P16234 | 10/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 6/20 | 1.00 |
| ▸ | PRKCA | P17252 | 3/20 | 0.78 |
| ▸ | EGFR | P00533 | 2/20 | 0.78 |
| ▸ | JAK3 | P52333 | 1/20 | 0.78 |
| ▸ | BTK | Q06187 | 1/20 | 0.78 |
| ▸ | ITK | Q08881 | 1/20 | 0.78 |
| ▸ | KIT | P10721 | 3/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4803395 | 0.93 | PDGFRA (0.87) | ABL1BCRPDGFRAPDGFRBPRKCA | |
| SCHEMBL23246300 | 0.93 | ABL1 (0.86) | ABL1BCRPDGFRAPDGFRBPRKCA | |
| SCHEMBL4801110 | 0.92 | ABL1 (0.84) | ABL1BCRPDGFRAPDGFRBPRKCA | |
| SCHEMBL1927373 | 0.90 | ABL1 (0.82) | ABL1BCRPDGFRAPDGFRBPRKCA | |
| Cyclohexane SCHEMBL5776157 | 0.90 | ABL1 (0.81) | ABL1BCRPDGFRAPDGFRBPRKCA | |
| SCHEMBL19556647 | 0.89 | ABL1 (0.80) | ABL1BCRPDGFRAPDGFRBPRKCA | |
| SCHEMBL2004455 | 0.89 | PDGFRA (0.91) | ABL1BCRPDGFRAPDGFRBPRKCA | |
| SCHEMBL29366684 | 0.89 | ABL1 (0.83) | ABL1BCRPDGFRAPDGFRBPRKCA | |
| SCHEMBL28677768 | 0.89 | ABL1 (0.83) | ABL1BCRPDGFRAPDGFRBPRKCA | |
| SCHEMBL4897200 | 0.89 | PDGFRA (0.88) | ABL1BCRPDGFRAPDGFRBPRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10828300-B2 | Substituted 2,4-diaminopyrimidines as kinase inhibitors | CELGENE CAR LLC (BM) | 2020-11-10 | — | — | US | disclosed |
| US-20190117650-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2019-04-25 | — | — | US | disclosed |
| US-9809603-B1 | Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same | DEUTERX, LLC (US) | 2017-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10828300-B2 | Substituted 2,4-diaminopyrimidines as kinase inhibitors | ABL1, DCK, ERBB2 | ABL1 1/4885BCR 782/4885PDGFRA 362/4885 |
| US-20190117650-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | ABL1 49/4885BCR 2095/4885PDGFRA 2240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.